PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kirstein, A. ; Schmid, T.E. ; Combs, S.E.

The role of miRNA for the treatment of MGMT unmethylated glioblastoma multiforme.

Cancers 12:1099 (2020)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Glioblastoma multiforme (GBM) is the most common high-grade intracranial tumor in adults. It is characterized by uncontrolled proliferation, diffuse infiltration due to high invasive and migratory capacities, as well as intense resistance to chemo- and radiotherapy. With a five-year survival of less than 3% and an average survival rate of 12 months after diagnosis, GBM has become a focus of current research to urgently develop new therapeutic approaches in order to prolong survival of GBM patients. The methylation status of the promoter region of the O-6-methylguanine-DNA methyltransferase (MGMT) is nowadays routinely analyzed since a methylated promoter region is beneficial for an effective response to temozolomide-based chemotherapy. Furthermore, several miRNAs were identified regulating MGMT expression, apart from promoter methylation, by degrading MGMT mRNA before protein translation. These miRNAs could be a promising innovative treatment approach to enhance Temozolomide (TMZ) sensitivity in MGMT unmethylated patients and to increase progression-free survival as well as long-term survival. In this review, the relevant miRNAs are systematically reviewed.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
6.126
1.445
9
15
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Glioblastoma ; Mirna ; Mgmt ; Survival ; Radiotherapy ; Chemotherapy ; Temozolomide ; Translational Medicine; Temozolomide Plus O-6-benzylguanine; Newly-diagnosed Glioblastoma; Dna-repair Protein; Human Glioma-cells; Cancer Stem-cells; Phase-ii; Malignant Progression; Adjuvant Temozolomide; Current Strategies; Genetic Pathways
Language english
Publication Year 2020
HGF-reported in Year 2020
ISSN (print) / ISBN 2072-6694
Journal Cancers
Quellenangaben Volume: 12, Issue: 5, Pages: , Article Number: 1099 Supplement: ,
Publisher MDPI
Publishing Place St Alban-anlage 66, Ch-4052 Basel, Switzerland
Reviewing status Peer reviewed
Institute(s) Institute of Radiation Medicine (IRM)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Radiation Sciences
PSP Element(s) G-501300-001
DOI 10.3390/cancers12051099
WOS ID WOS:000539246000040
Scopus ID 85085024360
PubMed ID 32354046
Erfassungsdatum 2020-05-12
[➜Report correction]